90 Results for "

VEGFR-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (90)

90 Results for "VEGFR-IN-1" in MCE Product Catalog:

Cat. No.: HY-101219
CAS No.: 269390-69-4
Purity:  98.42%
Target:  

VEGFR c-Kit EGFR

Research Areas:  

Cancer

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively [1].
loading...
    loading...
101
101 Publications Verification
Cat. No.: HY-10981
CAS No.: 417716-92-8
Purity:  99.75%
Synonyms: E7080
Target:  

VEGFR FGFR PDGFR c-Kit RET

Research Areas:  

Cancer

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
loading...
    loading...
101
101 Publications Verification
Cat. No.: HY-10981A
CAS No.: 857890-39-2
Purity:  99.86%
Synonyms: E7080 mesylate
Target:  

VEGFR FGFR PDGFR RET c-Kit

Research Areas:  

Cancer

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
loading...
    loading...
96
96 Cited Publications
Cat. No.: HY-10331
CAS No.: 755037-03-7
Purity:  99.93%
Synonyms: BAY 73-4506
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity [1].
loading...
    loading...
96
96 Cited Publications
Cat. No.: HY-10331A
CAS No.: 1019206-88-2
Purity:  99.96%
Synonyms: BAY 73-4506 monohydrate
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity [1].
loading...
    loading...
96
96 Cited Publications
Cat. No.: HY-13308
CAS No.: 835621-07-3
Purity:  99.58%
Synonyms: BAY 73-4506 hydrochloride
Target:  

VEGFR Autophagy PDGFR Raf RET

Research Areas:  

Cancer

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively [1].
loading...
    loading...
79
79 Cited Publications
Cat. No.: HY-10374
CAS No.: 204005-46-9
Purity:  99.96%
Synonyms: SU5416
Target:  

VEGFR

Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM [1].
loading...
    loading...
74
74 Cited Publications
Cat. No.: HY-50904
CAS No.: 656247-17-5
Synonyms: BIBF 1120
Target:  

PDGFR VEGFR FGFR

Research Areas:  

Cancer

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
74
74 Cited Publications
Cat. No.: HY-11106
CAS No.: 656247-18-6
Purity:  99.96%
Synonyms: BIBF 1120 esylate
Target:  

PDGFR VEGFR FGFR

Research Areas:  

Cancer

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-10230
CAS No.: 120685-11-2
Purity:  99.91%
Synonyms: PKC412; CGP 41251
Research Areas:  

Cancer

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM [1] . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-10799
CAS No.: 1210945-69-9
Purity:  98.03%
Target:  

Complement System

Research Areas:  

Cancer

EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-50905
CAS No.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Research Areas:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [1] .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-10207
CAS No.: 692737-80-7
Purity:  99.75%
Synonyms: CHIR-258 lactate; TKI-258 lactate
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR

Research Areas:  

Cancer

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively [1].
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-10977
CAS No.: 475108-18-0
Purity:  99.80%
Synonyms: AV-951; KRN951
Target:  

VEGFR

Research Areas:  

Cancer

Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy [1].
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-10977A
CAS No.: 682745-41-1
Purity:  99.77%
Synonyms: AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate
Target:  

VEGFR

Research Areas:  

Cancer

Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy [1].
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-112467
CAS No.: 682745-40-0
Purity:  ≥99.0%
Synonyms: AV-951 hydrate; KRN951 hydrate
Target:  

VEGFR

Research Areas:  

Cancer

Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy [1].
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112306
CAS No.: 1442472-39-0
Purity:  98.21%
Synonyms: DCC-2618
Research Areas:  

Cancer

Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10228
CAS No.: 453562-69-1
Purity:  99.96%
Synonyms: AMG 706
Target:  

c-Kit VEGFR

Research Areas:  

Cancer

Motesanib (AMG 706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10229
CAS No.: 857876-30-3
Purity:  99.86%
Synonyms: AMG 706 Diphosphate
Target:  

c-Kit VEGFR

Research Areas:  

Cancer

Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10337
CAS No.: 649735-46-6
Purity:  99.45%
Synonyms: BMS-540215
Target:  

VEGFR Autophagy

Research Areas:  

Cancer

Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β [1].
loading...
    loading...